drugset / Trial / NCT07076290

A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD

NCT07076290 ↗

Phase 1 Not yet recruiting 27 enrolled Rise Therapeutics LLC
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)

Timeline

Start
2026-09-01
Primary completion
2028-04-30
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject R-3750 Other / unclassified — Oral